


# Your quick guide to ordering and storing VAXNEUVANCE

## Ordering information

### READY TO ORDER?

You can place your order by:

- ✓ Contacting your local Merck representative
- ✓ Reaching out to your supplier
- ✓ Visiting [www.MerckVaccines.com](http://www.MerckVaccines.com)<sup>®</sup>



Not shown at actual size.

**NDC 0006-4329-03**

Package containing (10) 0.5-mL prefilled syringes

**CPT Code 90671<sup>1</sup>**

## Storage information



VAXNEUVANCE is supplied as a carton of ten 0.5-mL single-dose prefilled syringes with tip caps



Do NOT freeze



Must be refrigerated at 2°C to 8°C (36°F to 46°F)



Must be protected from light

CPT, Current Procedural Terminology.  
CPT is a registered trademark of the American Medical Association.

## Indications and Usage

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.


## Select Safety Information

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status and the potential benefits and possible risks.

(Select Safety Information continues on the next page)

 **Vaxneuvance<sup>®</sup>**  
Pneumococcal 15-valent  
Conjugate Vaccine

# Dosing and recommendations for VAXNEUVANCE

VAXNEUVANCE is administered as a 4-dose series at 2, 4, 6, and 12 through 15 months of age.



VAXNEUVANCE is a CDC, AAP, and AAFP recommended pneumococcal conjugate vaccine option for your pediatric patients<sup>2-5</sup>

VAXNEUVANCE can be given with other routinely administered pediatric vaccines<sup>d</sup>



<sup>a</sup>Dose 1 may be given as early as 6 weeks of age.

<sup>b</sup>The recommended interval between doses is 4 to 8 weeks.

<sup>c</sup>The 4<sup>th</sup> dose should be administered at approximately 12 through 15 months of age and at least 2 months after the 3<sup>rd</sup> dose.

<sup>d</sup>These vaccines include *Pentacel*, RECOMBIVAX HB<sup>®</sup>, RotaTeq<sup>®</sup>, M-M-R<sup>®</sup>II, VAQTA<sup>®</sup>, VARIVAX<sup>®</sup>, and *Hiberix*.

AAFP, American Academy of Family Physicians; AAP, American Academy of Pediatrics; CDC, Centers for Disease Control and Prevention.

## Select Safety Information (*continued*)

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever  $\geq 38.0^{\circ}\text{C}$  (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

**Before administering VAXNEUVANCE, please read the accompanying [Prescribing Information](#). The [Patient Information](#) also is available.** For additional copies of the Prescribing Information, please call 800-672-6372, visit [MerckVaccines.com](https://MerckVaccines.com)<sup>®</sup>, or contact your local Merck representative.

**References:** 1. Immunization Information Systems (IIS). CPT Codes Mapped to CVX Codes. Centers for Disease Control and Prevention. Last reviewed December 21, 2023. Accessed January 16, 2024. <https://www2a.cdc.gov/vaccines/iis/standards/vaccines.asp?rpt=cpt> 2. Farrar JL, Gierke R, Andrejko KL, et al. ACIP updates: recommendations for use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. Supplement. *MMWR Morb Mortal Wkly Rep*. 2023;72(39):1072. <https://stacks.cdc.gov/view/cdc/133252> 3. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2024. Centers for Disease Control and Prevention (CDC). Last reviewed November 16, 2023. Accessed November 16, 2023. <https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf> 4. Immunizations. American Academy of Pediatrics (AAP). Last updated July 10, 2023. Accessed July 13, 2023. <https://www.aap.org/en/patient-care/immunizations/> 5. American Academy of Family Physicians (AAFP). Immunization schedules. 2024. Accessed November 29, 2023. <https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/immunization-schedules.html>

